Efficacy evaluation | PR | SD | PD | |
---|---|---|---|---|
No of total patients | 6 | 17 | 7 | |
Gender | Male | 4(66.67%) | 16(94.12%) | 5(71.43%) |
Female | 2(33.33%) | 1(5.88%) | 2(28.57%) | |
Age(years) | P = 0.8784 (PR vs. SD) P = 0.7409 (PR vs. PD) P = 0.3373 (SD vs. PD) | 59.50 ± 9.73 | 62.17 ± 10.18 | 54.71 ± 13.91 |
Height(cm) | P = 0.1646 (PR vs. SD) P = 0.8785 (PR vs. PD) P = 0.1646 (SD vs. PD) | 161.33 ± 9.11 | 165.47 ± 5.18 | 161.86 ± 5.15 |
Weight(Kg) | P = 0.8951 (PR vs. SD) P = 0.5347 (PR vs. PD) P = 0.8651 (SD vs. PD) | 60.50 ± 15.24 | 59.76 ± 11.93 | 56.43 ± 5.99 |
BMI(Kg/m2) | P = 0.4892 (PR vs. SD) P = 0.5287 (PR vs. PD) P = 0.9610 (SD vs. PD) | 22.97 ± 5.15 | 21.70 ± 3.65 | 21.61 ± 2.81 |
Smoking History | Non-smoker | 2(33.33%) | 2(11.76%) | 1(14.29%) |
Former smoker | 4(66.67%) | 15(88.24%) | 6(85.71%) | |
ECOG performance status | 0 | 3(50.00%) | 5(29.41%) | 2(28.57%) |
1 | 3(50.00%) | 12(70.59%) | 5(71.43%) | |
Histology | Squamous cell carcinoma | 3(50.00%) | 7(41.18%) | 5(71.43%) |
Adenocarcinoma | 3(50.00%) | 10(58.82%) | 2(28.57%) | |
Stage | IIIb-IIIc | 3(50.00%) | 2(11.76%) | 0(0.00%) |
IV | 3(50.00%) | 15(88.24%) | 7(100.00%) | |
Metastatic | Liver | 2(33.33%) | 2(11.76%) | 1(14.29%) |
Brain | 1(16.67%) | 2(11.76%) | 1(14.29%) | |
Bone | 2(33.33%) | 5(29.41%) | 3(42.86%) | |
Lung | 2(33.33%) | 10(58.82%) | 4(57.14%) | |
Pleural metastasis | 0(0.00%) | 3(17.65%) | 1(14.29%) | |
PD-L1 status test | Data unavailable | 3(50.00%) | 3(17.65%) | 3(42.86%) |
0% | 1(16.67%) | 2(11.76%) | 2(28.57%) | |
1–49% | 1(16.67%) | 3(17.65%) | 2(28.57%) | |
≥ 50% | 1(16.66%) | 9(52.94%) | 0(0.00%) |